On July 23, Argenx SE rose 6.88% in regular trading, trading at $910.195/share, with turnover of $254 million. The surge was driven by the company's Q2 earnings report released before market open, which significantly exceeded Wall Street expectations.

Argenx reported Q2 earnings per share of $7.32, beating the analyst consensus estimate of $6.24 by 17.31%, representing a 95.72% year-over-year increase. Revenue came in at $1.542 billion, surpassing the $1.442 billion estimate. Product net sales reached $1.516 billion, up 60% year-over-year and 17% sequentially. Quarterly net income climbed to $472 million, nearly doubling from $245 million in the prior-year period. For the first half, cumulative product net sales reached $2.813 billion with net income of $838 million.

The strong results were fueled by continued momentum in its core product Vyvgart, which recently received FDA approval expanding its use to all serotypes of generalized myasthenia gravis. The company's cash position stood at $5.2 billion as of June 30, supporting ongoing clinical development across an expected 10 drug molecules by year-end.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)